University of Oxford researchers have developed personalized cancer treatments using artificial intelligence (AI).

The new approach incorporates deep reinforcement learning (DRL) into adaptive therapy strategies.

This method has shown promising results, particularly in prostate cancer patients, potentially doubling the time to relapse compared to standard methods.

The AI model used is interpretable, providing clinicians with actionable treatment strategies.

This innovation could revolutionize cancer management and improve patient outcomes.

AI and machine learning (ML) are also being explored for enhancing outcomes in patients with Pancreatic Ductal Adenocarcinoma (PDAC).

These technologies offer new possibilities for early intervention, risk prediction, and treatment strategies.

Further studies are planned to refine the personalized treatment method and extend its application to other cancer types.

The research signals a transformative shift in cancer care.